Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat

(Length of Discussion: 11 min)

Ashish Kamat, MD, MPH and Alicia Morgans, MD discuss non-muscle invasive bladder cancer, where the field stands particularly for BCG refractory patients and the definition of the BCG unresponsive patient. Ashish overviews the efforts of the SUO-CTC Bladder Committee and important updates and trials in this disease state.  

Biographies: 
Ashish M. Kamat, MD

Alicia Morgans, MD, MPH

Further Related Content:

A Phase III, Open-Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - NCT02773849

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - NCT02844816

Emerging Therapies for BCG-Unresponsive Non-muscle Invasive Bladder Cancer- EVERYDAY UROLOGY: Full Text article